clinical trial · NCT05054309
A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
Société des Produits Nestlé (SPN)·N/A·completed·n = 146
IBS - Irritable Bowel SyndromeBifidobacterium longum
brief summary
This is a prospective, randomized, placebo-controlled, double-blind, multi-center parallel- design study to evaluate the effect of BL NCC3001 in subjects with Irritable Bowel Syndrome.
started
Feb 11, 2022
primary completion
Dec 4, 2024
completion
Feb 14, 2025
last updated
Feb 28, 2025
official title
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol